Takeda Divests Techpool to Joint-Venture Partners in China
Takeda Divests Techpool to Joint-Venture Partners in China
Osaka, Japan, May 21, 2018 — Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced it has entered into an agreement to sell its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma Co (Techpool), a leader in the research, discovery and marketing of urinary protein biopharmaceuticals and production of biopharmaceuticals in critical care. The shareholding is to be acquired in an all-cash, combined Stock Purchase Agreement by Takeda’s joint venture partner in Techpool: Shanghai Pharmaceutical Holding Co. Ltd. (Shanghai Pharma SSE ticker: 601607, HKEx ticker: 2607) and a fund managed by SFund International Investment Fund Management Limited, a wholly-owned subsidiary of Guangzhou Industrial Investment Fund Management Co., Ltd (“the Fund”).
The agreement remains subject to approval from the State Administration for Market Regulation in the People’s Republic of China. The Base Payment for the purchase price of Takeda’s shareholding is US$280 million.
“This agreement provides Takeda with even greater focus to continue to meet the unmet needs of patients in China, and maintain our position as ‘best-in-class’ in our global therapeutic areas of focus, especially Gastroenterology and Oncology,” said Sean Shan, President, Takeda China and Area Head, Takeda Greater China. “Takeda is committed to China and will continue to strive to keep patients at the center of everything we do, both locally and across the globe.”
The Emerging Markets, including China, are a key growth driver for Takeda with recent local government reforms by China’s health authorities looking set to accelerate and reward innovation. In partnership with them, Takeda aims to launch up to seven (7) innovative products in the country within the next five years, to help meet the unmet needs of patients.
“This acquisition marks a strategic milestone for Shanghai Pharma in developing into a branded pharmaceutical manufacturer, and in building a first-class, domestic marketing organization,” commented Mr. Zhou Jun, Chairman of Shanghai Pharma. “We believe via acquisitions such as this, and our overall strategy, Shanghai Pharma has an important role to play in the China government’s ‘Healthy China’ policy.”
Techpool’s portfolio of innovative medicines include: Roan® (Ulinastatin for Injection), a treatment for acute and chronic pancreatitis, Kallikrein for mid-moderate acute thrombotic cerebral infarction, and Kailikang® (Urinary Kallidinogenase for Injection). These will remain under the management of Techpool. In addition, all current Techpool operations, and company assets - including its manufacturing facility in Guangzhou province - will continue to be owned and managed by Techpool, and its current staff will be retained as Techpool employees.
“The divestment to our current JV partners also ensures the uninterrupted supply of Techpool’s portfolio of medicines to patients, who are our primary focus,” concluded Mr. Shan.
“Shanghai Pharma will work closely with Techpool to break new ground and unleash the growth potential of its core products through targeted market access, marketing management systems, and a nationwide distribution network so as to create momentum to maintain sustainable growth,” concluded Mr. Zhou.
Upon completion of the transaction, the Fund will purchase approximately 49% of the Takeda shareholding, and Shanghai Pharma will acquire approximately 51% of it. As a result, Shanghai Pharma’s ownership of Techpool will rise to about 67% from around 41%, making them majority shareholders. the Fund’s purchase will result in indirect ownership of around 25% of Techpool.The outstanding 8% of Techpool’s shares will remain unchanged under the ownership of the Guangzhou Financial Innovation Investment Holding Co., Ltd.,a wholly-owned subsidiary of Guangzhou Industrial Investment Fund Management Co., Ltd.
Further financial details of the agreement will only be disclosed in accordance with any associated regulatory requirements.
About Techpool
Guangdong Techpool Bio-Pharma Co., Ltd. is a leading manufacturer of bio-protein pharmaceuticals. Headquartered in Guangzhou, China its operations span R&D, manufacturing/production and Sales & Marketing. Following EMEA (Europe) and US FDA standards, Techpool has state-of-the-art production lines for APIs and finished dosage forms. It was the first Guangzhou-based enterprise to receive the latest GMP certification. Focusing on critical care, Techpool’s two flagship products are Roan®, for the treatment of acute and chronic pancreatitis and acute circulatory failure (shock), and Kailikang® for mild to moderate acute thrombotic cerebral infarction. In 2017, Techpool was awarded the status of “Top 10 Chinese Pharmaceutical Enterprise with Highest Investment Value.”
About Shanghai Pharma
Shanghai Pharmaceuticals Holding Co., Ltd. (SSE ticker: 601607, HKEx ticker: 2607), is a leading pharmaceutical manufacturer and healthcare services provider in China. More information can be accessed at http://english.sphchina.com
About SFund
SFund International Investment Fund Management Limited is a wholly-owned subsidiary and an international investment and financing platform of the Guangzhou Industrial Investment Fund Management Co., Ltd., a leading investment and financing company through which the Guangzhou Municipal Government promotes the transformation and upgrading of local industries and urban development in Guangzhou province, China. More information can be accessed at http://www.sfund.com.
About Takeda
Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in Emerging Markets, are currently fuelling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.
Media Contacts:
Media outside Japan
Vince Docherty
[email protected]
+65 8332 4233
Japanese Media
Kazumi Kobayashi
[email protected]
+81 (0) 3-3278-2095